Apellis Pharmaceuticals Inc(APLS)stock report

Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases. The Company’s lead compounds are designed to inhibit complement component 3 (C3), the central protein in the complement cascade. The Company is developing APL-2 for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) by subcutaneous injection, which is an injection into the tissue under the skin. It is developing APL-2 for the treatment of geographic atrophy (GA) and intermediate age-related macular degeneration (AMD) by intravitreal injection, which is an injection into the eye. The Company is developing APL-1 for the treatment of chronic obstructive pulmonary disease (COPD) by inhaled administration.

Market Cap:2400M; Shares Outstanding:63.9M; Short Interest: 11.77%; Q3 2019(9/30/19): Cash 434M. Loss 69M

EPS and Sales:

Date EPS % last year % last quarter
2018.12.31 -2.34 36.41% -38.46%
2019.3.31 -0.87 -102.33% 62.82%
2019.6.30 -2.01 -91.43% -27.00%
2019.9.30 -2.79 100.00% -38.81%



Insider Transactions:

Institution Ownership:

Total institutions: 144,no change
Shares hold: 42026.3k shares. no change
shares% hold: 65.78%,no change

Analyst Ratings:

2020.01.08: Apellis Pharma prices stock offering at $37k

2020.01.07: Apellis Pharma’s APL-2 successful in PNH study; shares up 49% premarket

Leave a Reply